Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
LFCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.68 - $8.45
Previous CloseN/A
Volume140.23K
Average Volume (3M)156.84K
Market Cap
$207.71M
Enterprise Value$417.37M
Total Cash (Recent Filing)$9.46M
Total Debt (Recent Filing)$12.31M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Apr 02, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding37,025,330
10 Day Avg. Volume110,550
30 Day Avg. Volume156,838
Standard Deviation0.20
R-Squared0.07
Alpha-0.00461
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.59
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.97
Enterprise Value/Ebitda-358.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Lifecore Biomedical News
PremiumCompany Announcements
Lifecore Biomedical’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Lifecore Biomedical Reports Q2 Fiscal 2025 Results
---
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityThe sale of Lifecore's excess capital equipment provides $17 million in cash and enhances financial flexibility.
Growth OpportunitiesThe company has 25 active development projects with an incremental $100-200 million in commercial revenue potential, with 10 projects in later stage development expected to begin generating revenue in the 2026-2028 timeframe.
Bears Say
Leverage ConcernsLifecore's balance sheet remains highly leveraged with approximately $180.1 million in debt and $44.3 million in convertible preferred stock.
---
Ownership Overview
28.99% Insiders
5.64% Mutual Funds
48.84% Other Institutional Investors
8.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $3.68 and its highest was $8.45 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $207.71M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Apr 02, 2025 which is in 31 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Jan 02, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.04.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Overvalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate is -0.14.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,025,330 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went up 14.414%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
---
Lifecore Biomedical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
LFCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $97.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
-29.58%
Trailing 12-Months
Asset Growth
3.89%
Trailing 12-Months
Company Description
Lifecore Biomedical
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Clara, CA.
---
LFCR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
While Lifecore demonstrated notable growth in revenue, gross profit, and adjusted EBITDA, alongside successful financing and credit restructuring, the net loss and increased expenses present challenges that must be addressed. However, the strategic initiatives and leadership changes indicate a positive trajectory for future growth.Read More>---
LFCR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering LFCR
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+1.36%
assigned a buy rating 2 months ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +1.36% per trade.
---